View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 24, 2016updated 13 Jul 2022 10:13am

Merck reports positive Phase III ONCEMRK trial of Isentress to treat HIV-1 infection

US-based pharmaceutical company Merck has reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat adults with HIV-1 infection.

US-based pharmaceutical company Merck has reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat adults with HIV-1 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Isentress inhibits integrase for the treatment of HIV-1 infection in adult and pediatric patients aged four weeks and older and weighing at least 3kg as part of combination HIV therapy.

It blocks the integrase enzyme from inserting HIV-1DNA into human DNA thereby demonstrating a rapid anti-viral activity.

The blockage of integrase limits the ability of the virus to replicate and infect new cells.

"It is important for patients living with HIV-1 to have additional therapeutic options for the treatment of HIV-1 infection to meet their diverse needs."

The multicentre, double-blind, randomised, active comparator-controlled ONCEMRK trial is designed to evaluate the safety and efficacy of combination of raltegravir, Isentress each in combination with Truvada in previously untreated HIV-1 infected adult patients.

The trial was primarily focused on limiting the number of HIV RNA achieved by the patients at week 48 of the study, while the secondary objective is to determine the change from baseline in CD4 cell counts and tolerability at Week 48.

After 48 weeks of the therapy, data suggested a non-inferior safety and efficacy of raltegravir when compared to the approved dosage of Isentress, both of which is in combination with Truvada.

Juan A. Fernandez Hospital, Buenos Aires, Argentina infectious disease unit chief Dr Pedro Cahn said: “It is important for patients living with HIV-1 to have additional therapeutic options for the treatment of HIV-1 infection to meet their diverse needs."

Based on the findings of the trial, the European Medicines Agency (EMA) has approved the file for the investigational once-daily formulation of Isentress for review.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena